Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
GIP (glucose-dependent insulinotropic polypeptide) activation enhances insulin secretion and appears to modulate how the body stores and burns fat
Same calories
Bellwether Trial Selection: In late 2025, the court is expected to select several "bellwether" cases to proceed to early trial
GLP-1 agonists is currently approved as second/third-line therapy for T2DM patients with inadequate glycaemic control (HbA1c 7.0 or 53 mmol/mol) despite lifestyle modifications and first-line antihyperglycaemics (metformin/sulfonylurea/insulin)
This dual action makes Semaglutide a popular choice for both weight loss and diabetes management
